Evercore ISI sets $23 target on MindMed stock, sees potential

Tuesday, Evercore ISI initiated coverage on MindMed shares (NASDAQ:MNMD) with an Outperform rating and a price target of $23.00, well above the current trading price of $6.90. The research firm's move underscores its positive outlook on the company's prospects in the neurology and neuro-psychiatry sectors. According to InvestingPro data, analyst consensus is strongly bullish, with price targets ranging from $16 to $55.

MindMed is at the forefront of developing novel therapies for generalized anxiety disorder (GAD), which affects over 35 million individuals in the United States, and major depressive disorder (MDD), with a prevalence of over 22 million in the U.S. The company's lead compound, a novel oral formulation of LSD named MM120, has shown promising results in a Phase 2b trial for GAD, highlighting its potential efficacy and durability. InvestingPro analysis shows the company maintains a strong financial position with a current ratio of 9.0 and more cash than debt on its balance sheet.

The company is gearing up for Phase 3 trials for both GAD and MDD, with expected data releases in the first and second halves of 2026. This progression into late-stage development marks a significant step for MindMed as it moves closer to potentially bringing new treatment options to market.

Evercore ISI's price target of $23.00 suggests a substantial upside from the current trading levels. The target market capitalization of $1.8 billion reflects a roughly 1.5 times risk-adjusted peak sales multiple according to the research firm's analysis.

The positive sentiment from Evercore ISI comes amid a broader interest in the neuropsychiatric space, which has seen a flurry of investment activity including mergers and acquisitions, initial public offerings, and significant private financing. MindMed's advancements in this area position it within a dynamic and growing field of medicine. The stock has shown strong momentum with an 87% return over the past year, though InvestingPro analysis indicates the company is currently trading below its Fair Value. Subscribers can access detailed financial health scores and 8 additional ProTips for deeper insight into MNMD's investment potential.

In other recent news, Mind Medicine, also known as MindMed, has been selected to join the Nasdaq Biotechnology Index, a significant milestone that recognizes the company's potential to create long-term shareholder value. MindMed's experimental treatment for Generalized Anxiety Disorder, MM120 ODT, has received an Innovation Passport from the U.K. Medicines and Healthcare products Regulatory Agency, accelerating the development and access of new medicines in the U.K.

Key appointments within the company include Dr. Javier A. Muniz as Vice President of Research and Development Strategy, and Dr. Gregg A. Pratt as the Chief Regulatory and Quality Assurance Officer. These appointments come as MindMed prepares for three Phase 3 studies of MM120 ODT.

In financial developments, the company has swapped 8 million common shares for pre-funded warrants and initiated a public offering of common shares and pre-funded warrants, expecting to raise approximately $75 million.

Analysts from Canaccord Genuity, H.C. Wainwright, and Roth/MKM have provided their ratings on MindMed. Canaccord Genuity maintained its Buy rating on MindMed, H.C. Wainwright increased its price target and reaffirmed a Buy rating, and Roth/MKM initiated coverage on MindMed with a Buy rating. These ratings followed the FDA's recognition of MM120 with a breakthrough designation for treating Generalized Anxiety Disorder.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.